Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory Mature B-cell Neoplasms
NCT06508931Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2025
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of zamtocabtagene autoleucel in B-cell neoplasm, sponsored by Miltenyi Biomedicine GmbH. Started Aug 2025; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
B-cell neoplasm
Beyond the preview
Go deeper on NCT06508931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508931.